1. B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer
- Author
-
C. Simopoulos, Alexandra K. Tsaroucha, E. Chatzitheoklitos, G. Tripsianis, Maria Lambropoulou, Anastasia Tsiaousidou, and C. Tsompanidou
- Subjects
Adult ,Male ,Oncology ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Protein Deglycase DJ-1 ,HSP27 Heat-Shock Proteins ,Adenocarcinoma ,Deoxycytidine ,Antigen ,Internal medicine ,Pancreatic cancer ,Biomarkers, Tumor ,medicine ,Humans ,Pathological ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Oncogene Proteins ,Gastrointestinal tract ,Chemotherapy ,Hepatology ,business.industry ,Intracellular Signaling Peptides and Proteins ,Gastroenterology ,Middle Aged ,V-Set Domain-Containing T-Cell Activation Inhibitor 1 ,Prognosis ,medicine.disease ,Immunohistochemistry ,Survival Analysis ,Gemcitabine ,Pancreatic Neoplasms ,Drug Resistance, Neoplasm ,Female ,CA19-9 ,business ,medicine.drug - Abstract
Objectives: Pancreatic cancer (PC) is one of the most lethal tumors of the gastrointestinal tract. The ability to predict which patients would benefit most from surgical intervention and chemotherapy would be a great clinical tool. A large number of potential markers have been identified lately in pancreatic cancer and their clinical utilities as prognostic tools are under investigation. Methods: We recruited 41 patients who had undergone radical surgical resection for PC between 2003 and 2010. To investigate the prognostic factors, we evaluated 3 possible markers: B7H4, HSP27 and DJ-1 protein expressions in the tissue specimens of these 41 patients by immunohistochemistry and analyzed the clinical and pathological features of these specimens. Results: The expression of the three antigens was independently associated with a negative impact of chemotherapy with gemcitabine on patient’s survival. Moreover, patients who overexpressed B7H4 had worse prognosis than the ones who did not. Conclusions: B7H4, DJ-1 and HSP27 may be used in the future as prognostic markers that express resistance of pancreatic cancer patients to chemotherapy with gemcitabine.
- Published
- 2013
- Full Text
- View/download PDF